Targeted Therapy for Malignant Gliomas

作者: Maame Dankwah-Quansah , Antonio M. Omuro

DOI: 10.1007/978-94-007-0344-5_31

关键词:

摘要: Malignant gliomas, including anaplastic astrocytomas, oligodendrogliomas and glioblastomas are aggressive primary brain tumors associated with dismal prognosis. The standard treatment for consists of temozolomide radiotherapy, but virtually all patients recur, a fatal disease outcome. Molecular targeted therapy has been the focus attention in development new treatments malignant gliomas. Many signaling pathways that could potentially be have described, P13k/Akt/mTOR, Ras/MAPK, others. Unfortunately, first generation trials gliomas disappointing. While strategies targeting angiogenesis through VEFGR pathway inhibition shown promising activity, results single agent several other drugs largely negative. Current research is focusing on combination different agents multi-targeted treatments, as well patient selection based pre-existing molecular characteristics. In this chapter we review issues encountered previously conducted, future venues.

参考文章(32)
David F. Stefanik, Wendy K. Fellows, Laila R. Rizkalla, Waheeb M. Rizkalla, Paulette P. Stefanik, Albert B. Deleo, William C. Welch, Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. Journal of Neuro-oncology. ,vol. 55, pp. 91- 100 ,(2001) , 10.1023/A:1013329832067
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
Andreas von Deimling, Jimmy T. Efird, John W. Henson, David N. Louis, Yasuhiro Ono, Keisuke Ueki, CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated Cancer Research. ,vol. 56, pp. 150- 153 ,(1996)
Paul Cairns, David Sidransky, Janusz Puc, Jeffrey N. Bruce, Steven I. Wang, Ramon Parsons, Jing Li, Somatic mutations of PTEN in glioblastoma multiforme. Cancer Research. ,vol. 57, pp. 4183- 4186 ,(1997)
Judah Folkman, Ezio Merler, Charles Abernathy, Gretchen Williams, ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS Journal of Experimental Medicine. ,vol. 133, pp. 275- 288 ,(1971) , 10.1084/JEM.133.2.275
S. Y. Cheng, H. J. Huang, M. Nagane, X. D. Ji, D. Wang, C. C. Shih, W. Arap, C. M. Huang, W. K. Cavenee, Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor Proceedings of the National Academy of Sciences of the United States of America. ,vol. 93, pp. 8502- 8507 ,(1996) , 10.1073/PNAS.93.16.8502
Xiao‐Ping Zhou, You‐Jun Li, Khê Hoang‐Xuan, Pierre Laurent‐Puig, Karima Mokhtari, Michel Longy, Marc Sanson, Jean‐Yves Delattre, Gilles Thomas, Richard Hamelin, None, Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. International Journal of Cancer. ,vol. 84, pp. 150- 154 ,(1999) , 10.1002/(SICI)1097-0215(19990420)84:2<150::AID-IJC10>3.0.CO;2-#
Gregory Cairncross, Robert Jenkins, Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer Journal. ,vol. 14, pp. 352- 357 ,(2008) , 10.1097/PPO.0B013E31818D8178
M. Josefa Bello, Jesus Vaquero, Jose M. De Campos, M. Elena Kusak, Jose L. Sarasa, Javier Saez-Castresana, Angel Pestana, Juan A. Rey, Molecular analysis of chromosomh 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors International Journal of Cancer. ,vol. 57, pp. 172- 175 ,(1994) , 10.1002/IJC.2910570207
Patrick Y. Wen, Santosh Kesari, Malignant Gliomas in Adults The New England Journal of Medicine. ,vol. 359, pp. 492- 507 ,(2008) , 10.1056/NEJMRA0708126